The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...

On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

(THE CONVERSATION) Chronic pain affects hundreds of millions of people around the world. But the opioid crisis in North America led many health care providers to realize they relied too heavily on ...

It’s not cleared for chronic pain. “Today’s approval is an important public health milestone in acute pain management,” said Jacqueline Corrigan-Curay, MD, acting director of the FDA’s ...

Acute and chronic postoperative pain and functional disability persisted among patients who underwent posterior spinal fusion despite multimodal analgesic management.

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...

Vertex isn’t pursuing the FDA’s approval for suzetrigine to treat chronic ... t block acute pain better than opioids, he believes it is still likely to have a place in pain management. “ ...

It is important to add pain management to leprosy treatment protocols. This can reduce the challenges that patients face. Read on.